Reactivation of hepatitides B and C (HBV and HCV) is a known complication in the oncologic therapy.
An against B-cell relateted immunotherapy (e.g. rituximab / Mabthera) in B-cell lymphoma and the related reactivation of hepatitis B has been shown to be particularly significant.
Under these and other therapies it sometimes occur serious hepatitis progressions. A Chemotherapy-associated reactivated hepatitis often leads to a dose reduction, a pause or even a termination of the current therapy. This reduces the intended chances of success and thus the patient's outcome.
Our aim is to determine and evaluate the prevalence and incidence of hepatitides for ambulatory oncology patients in the"Südoldenburger Land".